Derrole Meroster
The COVID-19 pandemic has presented a multifaceted challenge to healthcare systems worldwide. Beyond the respiratory symptoms commonly associated with the disease, emerging evidence suggests a significant association between COVID-19 and venous thromboembolism. While much attention has been directed towards severe cases requiring intensive care, understanding the risk of VTE in patients receiving treatment outside of intensive care units is crucial. This article aims to explore the prevalence, risk factors, pathophysiology, diagnostic strategies and management of VTE in COVID-19 patients treated in non-ICU settings. Venous thromboembolism remains a significant concern in COVID-19 patients receiving treatment in non-ICU settings. Healthcare providers should maintain a high index of suspicion for VTE, especially in high-risk individuals and implement appropriate thromboprophylaxis and surveillance measures to mitigate the risk of thrombotic events. Further research is warranted to refine risk stratification algorithms and optimize VTE prevention strategies in this patient population.
分享此文章
English 
Spanish 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 